Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering AAV capsids.

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...

Roche has inked a new deal with Dyno Therapeutics to develop next-generation AAV capsids for gene therapies targeting ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Matica Biotechnology Inc. (Matica Bio), a CDMO specializing in viral vector development and manufacturing, announced the ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.

at 08:05 Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases Dyno Therapeutics, Inc., a genetic technologies company applying ...

But a session of E-tuning and another on an actual dyno was hugely beneficial to my humble Civic. Now, I’d tell anyone interested in hot rodding their car at all to look into computer tuning ...